<DOC>
	<DOCNO>NCT00085228</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop tumor cell divide stop grow die . Oblimersen may increase effectiveness docetaxel make tumor cell sensitive drug . PURPOSE : This randomized phase II trial study well give docetaxel together oblimersen work compare docetaxel alone treat patient hormone-refractory adenocarcinoma ( cancer ) prostate .</brief_summary>
	<brief_title>Docetaxel With Without Oblimersen Treating Patients With Hormone-Refractory Adenocarcinoma ( Cancer ) Prostate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare activity docetaxel without oblimersen , term prostate-specific antigen response , patient hormone-refractory adenocarcinoma prostate . - Compare toxicity regimens patient . Secondary - Compare time progression patient treat regimen . - Compare survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , metastatic disease ( M0 vs M1 non-measurable lesion vs M1 measurable lesion ) , prior estramustine ( yes v ) , prior bisphosphonates ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 5 oblimersen IV continuously day 1-7 . - Arm II : Patients receive docetaxel IV 1 hour day 1 . In arm , treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . Patients follow every 8 week progressive disease every 16 week thereafter . PROJECTED ACCRUAL : A total 102 patient ( 51 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Hormonerefractory disease Disease progression prior hormonal therapy luteinizing hormonereleasing hormone ( LHRH ) analogues orchiectomy antiandrogens ( give together consecutively ) Prostatespecific antigen ( PSA ) progression document least 2 increase PSA value previous PSA reference value Must demonstrate continue PSA elevation least 6 week discontinuation antiandrogen therapy PSA ≥ 5 ng/mL ( Hybritech equivalent ) within past week Testosterone ≤ 0.5 ng/mL* NOTE : *Patients medical castration LHRH analogue must continue LHRH analogue throughout study No evidence painful and/or destructive bone metastasis require concurrent radiotherapy , bisphosphonates , boneseeking radionuclides Other bone metastasis allow No clinical evidence brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,500/mm^3 Hemoglobin ≥ 10 g/dL Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ ULN PTT PT ≤ 1.5 time ULN OR INR ≤ 1.3 Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Cardiovascular No unstable angina No uncontrolled hypertension No deep venous thrombosis within past 6 month No cerebrovascular accident , transient ischemic attack , myocardial infarction within past 6 month Pulmonary No pulmonary embolism No history interstitial pneumonitis No history pulmonary fibrosis Other Adequate venous access HIV negative No active infection No preexisting neuropathy No hypersensitivity phosphorothioates No hypersensitivity oligonucleotides component oblimersen formulation drug formulate polysorbate No psychological , familial , sociological , geographical condition would preclude study compliance No malignancy within past 5 year except adequately treat superficial urothelial skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior estramustine allow No prior chemotherapy No concurrent estramustine Endocrine therapy See Disease Characteristics At least 6 week since prior flutamide , bicalutamide , nilutamide More 6 week since prior hormonal manipulation PCSPES Concurrent LHRH agonist allow No concurrent antiandrogens Radiotherapy See Disease Characteristics No prior radiotherapy involve &gt; 25 % marrowproducing area No prior boneseeking radionuclides No concurrent radiotherapy ( include palliative therapy painful bone metastasis ) No concurrent boneseeking radionuclides Surgery See Disease Characteristics Other Prior bisphosphonates allow No concurrent anticoagulation except lowdose warfarin ( 1 mg/day ) No concurrent regular ( daily ) intake opioid analgesic No concurrent experimental drug anticancer drug No concurrent bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>